ELHT Evidence Hub
  • Home
  • Meet the Team
  • Library Facilities
  • Education, Research and Innovation
Picture

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

20/9/2019

0 Comments

 
​Author(s) Clarke N.W.; Hoyle A.; Ali A.; Ingleby F.C.; Amos C.L. et al.
Source Annals of oncology : official journal of the European Society for Medical Oncology; Sep 2019
DOI 10.1093/annonc/mdz396
BACKGROUND: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naive prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients.

METHOD(S): We randomly allocated patients in 2:1 ratio to standard-of-care (SOC; control group) or SOC+docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional.

RESULT(S): Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n=724) or SOC+docetaxel (n=362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR=0.81, 95% CI 0.69-0.95, P=0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P=0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR=0.66, 95% CI 0.57-0.76, P<0.001) and progression-free survival (HR=0.69, 95% CI 0.59-0.81, P<0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P>0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1year without prior progression).

​CONCLUSION(S): The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naive prostate cancer patients regardless of metastatic burden.Copyright © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
  • Available in full text at Annals of oncology : official journal of the European Society for Medical Oncology from Unpaywall
0 Comments



Leave a Reply.

    The following databases were searched:
    EMBASE,  MEDLINE, PsycINFO, BNI, CINAHL, 
    to find  ELHT staff publications

    Specialties

    All
    ANAESTHETICS
    CARDIOLOGY
    COVID 19
    DERMATOLOGY
    DIABETES
    DIETETICS
    EMERGENCY CARE
    GYNAECOLOGY
    MAXILLOFACIAL
    NEONATOLOGY
    OBSTETRICS
    ONCOLOGY
    ORTHOPAEDICS
    PAEDIATRICS
    PAIN
    PHARMACY
    RADIOLOGY
    RESPIRATORY
    SURGERY
    UROLOGY
    VASCULAR SURGERY

    RSS Feed

    Archives - past 2 years

    December 2020
    November 2020
    October 2020
    September 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    January 2019
    December 2018

Learning Centre Library
Royal Blackburn Teaching Hospital
library.blackburn@elht.nhs.uk
01254 734312 or Ext 84312

​Find us

Staffed Opening Hours
Mon      08:30-16:30
Tue       08:30-16:30
Wed     08:30-16:30
Thu      08:30-16:30
Fri         08:30-16:00
Mackenzie Library
Burnley General Teaching Hospital
library.burnley@elht.nhs.uk
01282 803114 or Ext. 13114

Find us

Staffed Opening Hours
Mon      08:30-16:00
Tue       08:30-16:00
Wed     08:30-16:00
Thu       08:30-16:00
Fri         Unstaffed

FAQS
​Library Catalogue
Library @lerts
​Your Specialty or Professional Group
Membership Terms & Conditions
Privacy Policy
Our Performance
​Your Feedback
​Specialty Journals

Picture
Picture
24/7 access to the library is available - please see library staff
Picture
  • Home
  • Meet the Team
  • Library Facilities
  • Education, Research and Innovation